Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta-analysis.

Abstract

Entecavir (ETV) and Tenofovir disoproxil fumarate (TDF) are the first-line drugs for the treatment of chronic hepatitis B virus (HBV). However, the impact of these two antiviral agents on the outcome of HBV-related hepatocellular carcinoma (HCC) after curative therapy remains to be explored. The purpose of the present study was to compare the effect of ETV and TDF on recurrence and mortality after curative treatment for HBV-related HCC. A comprehensive literature search of multiple electronic databases was conducted from 2000 to January 2022 for studies comparing ETV and TDF for HBV-related HCC patients after curative therapy. The adjusted hazard ratios (aHR) were pooled using a random-effects model. A total of nine studies with 5298 patients were included in the final meta-analysis. TDF was associated with a lower risk of HCC recurrence [aHR 0.73, 95% confidence interval (CI) 0.65-0.81] compared to HCC. TDF reduced the risk of late recurrence compared to ETV (aHR 0.58, 95% CI 0.45-0.76) but not early recurrence (aHR 0.88, 95% CI 0.76-1.02). The mortality risk was also lower with TDF compared to ETV (aHR 0.62, 95% CI 0.50-0.77). TDF was associated with a lower risk of recurrence and mortality than ETV after resection or ablation of HBV-related HCC. Further prospective randomized controlled studies are warranted to validate these results.

• Authors: Suprabhat Giri, Dhiraj Agrawal, Shivaraj Afzalpurkar, Amrit Gopan, Sumaswi Angadi, Sridhar Sundaram
• Journal: Journal of viral hepatitis (J Viral Hepat) Vol. 30 Issue 2 Pg. 108-115 (02 2023) ISSN: 1365-2893 [Electronic] England
• PMID: 36321967 (Publication Type: Meta-Analysis, Systematic Review, Journal Article)
• Copyright: © 2022 John Wiley & Sons Ltd.

Chemical References

• Tenofovir
• entecavir
• Antiviral Agents

Topics

• Humans
• Tenofovir
• Hepatitis B, Chronic (complications, drug therapy)
• Carcinoma, Hepatocellular (drug therapy)
• Tertiary Prevention
• Liver Neoplasms (drug therapy)
• Antiviral Agents
• Hepatitis B virus
• Treatment Outcome